wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q40846805-1F8DF17C-462C-4A0D-9EC6-0FB0F95788C6
Q40846805-1F8DF17C-462C-4A0D-9EC6-0FB0F95788C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40846805-1F8DF17C-462C-4A0D-9EC6-0FB0F95788C6
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
P2860
Q40846805-1F8DF17C-462C-4A0D-9EC6-0FB0F95788C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40846805-1F8DF17C-462C-4A0D-9EC6-0FB0F95788C6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bdbac4b5ed724e799dd764b7accbc88e20ca1844
P2860
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.